P682: GO-CARE: a prospective multi-centre observational study of golimumab effectiveness and quality of life in a real life UC patient population in Italy
ECCO '19 Copenhagen
2019
P683: Higher serum golimumab concentrations are significantly associated with combined clinical-biochemical remission during maintenance therapy: results from the GO-LEVEL study
ECCO '19 Copenhagen
2019
P686: Neither high infliximab maintenance doses nor high trough levels trigger skin side effects of the drug: a prospective cross-sectional study
ECCO '19 Copenhagen
2019
P687: Clinical remission demonstrated with oral ozanimod in the overall population and across multiple subgroups of patients with moderately to severely active ulcerative colitis in the TOUCHSTONE trial
ECCO '19 Copenhagen
2019
P688: Ustekinumab in resistant Crohn’s disease: 1-year UK IBD tertiary referral centre ‘real-world’ experience
ECCO '19 Copenhagen
2019
P689: The effect of nutritional therapy on bone mineral density and bone metabolism in paediatric Crohn’s disease
ECCO '19 Copenhagen
2019
P690: Comparative efficacy of vedolizumab and adalimumab as second-line therapy in ulcerative colitis patients previously treated with infliximab
ECCO '19 Copenhagen
2019
P691: Trends in diagnostic prevalence and treatment patterns of adult ulcerative colitis patients in the USA, 2007–2017
ECCO '19 Copenhagen
2019
P692: Positive histological margins is a risk factor of recurrence after ileocaecal resection in Crohn’s disease
ECCO '19 Copenhagen
2019
P694: Genetic predisposition and thiopurine-induced pancreatitis in inflammatory bowel disease patients
ECCO '19 Copenhagen
2019
P695: Feasibility and safety of strictureplasties performed by laparoscopic approach for complicated Crohn’s disease: A prospective observational cohort study
ECCO '19 Copenhagen
2019
P696: Long-term prognosis and predictive factors for surgical treatment of intestinal lesions in patients with Behcet’s disease
ECCO '19 Copenhagen
2019
P697: Pneumocystis jirovecii pneumonia in IBD patients treated with immunomodulator(s)
ECCO '19 Copenhagen
2019
P698: Persistence, clinical effectiveness and safety of vedolizumab in the post-marketing real clinical practice in Italy: a double-centre, 2-year experience in Crohn’s disease and ulcerative colitis patients
ECCO '19 Copenhagen
2019
P699: Faecal microbiota transplantation as treatment for recurrent clostridium difficile infections: a single-centre experience
ECCO '19 Copenhagen
2019